 Pilot study sandostatin therapy refractory HIV-associated diarrhea Seventeen AIDS patients prospective open-label dose-finding study octreotide Sandostatin therapy refractory diarrhea nonevaluable due progression AIDS symptomatology lack confirmation HIV infection evaluable patients micrograms micrograms micrograms thrice daily doses sixth patient moderate reduction stool volume micrograms thrice relevant criteria response discontinuation therapy diarrhea patients days reinitiation octreotide patients treatment patients concurrent cryptosporidial infection treatment drug mild symptomatology patients Long-term treatment stable dose effective treated patients periods months moderate responder year patient dose increases symptoms year treatment severe nausea injections dose cessation patient partial control diarrhea months dose increases data octreotide useful therapeutic value HIV-associated diarrhea studies